نتائج البحث - "Luděk, Pour"

1

Slow increase of bilirubin concentration during administration of lenalidomide, bortezomib and dexamethasone for multiple myeloma (unmasking previously undiagnosed Gilbert syndrome) and disappearance of necrobiotic xanthogranuloma after complete remission of multiple myeloma

المؤلفون: Zdeněk Adam, Zdeněk Řehák, Zuzana Adamová, Luděk Pour, Klára Dvořáková, Barbora Packová, Renata Koukalová, Martin Krejčí, Marta Krejčí, Martin Štork, Viera Sandecká, Ivanna Boichuk, Zdeněk Král

المصدر: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 35(4)

مصطلحات موضوعية: Bortezomib, Oncology, Positron Emission Tomography Computed Tomography, Antineoplastic Combined Chemotherapy Protocols, Humans, Bilirubin, Gilbert Disease, Multiple Myeloma, Necrobiotic Xanthogranuloma, Lenalidomide, Dexamethasone, Hyperbilirubinemia

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e43b1daf11479ed71903aa455c714351Test
https://pubmed.ncbi.nlm.nih.gov/35989089Test

2

Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data

المؤلفون: Viera SANDECKA, Luděk POUR, Ivan ŠPIČKA, Jiří MINAŘÍK, Jakub RADOCHA, Tomáš JELÍNEK, Petr PAVLÍČEK, Alexandra JUNGOVÁ, Petr KESSLER, Marek WRÓBEL, Martin ŠTORK, Jan ŠTRAUB, Tomáš PIKA, Lenka ČÁPKOVÁ, Sabina ŠEVČÍKOVÁ, Vladimír MAISNAR, Roman HÁJEK

المصدر: Neoplasma. 69(6)

مصطلحات موضوعية: Cancer Research, Oncology, Antineoplastic Combined Chemotherapy Protocols, Humans, Multiple Myeloma, Dexamethasone, Czech Republic, Routinely Collected Health Data

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0549b45be2adbb252d16072e7e0e3d59Test
https://pubmed.ncbi.nlm.nih.gov/36591805Test

3

Bortezomib‐based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data

المصدر: European Journal of Haematology. 107:466-474

مصطلحات موضوعية: Male, Oncology, medicine.medical_specialty, Anemia, Newly diagnosed, Dexamethasone, Disease-Free Survival, Bortezomib, 03 medical and health sciences, 0302 clinical medicine, Autologous stem-cell transplantation, hemic and lymphatic diseases, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Registries, Cyclophosphamide, Melphalan, Multiple myeloma, Aged, Czech Republic, 030304 developmental biology, Aged, 80 and over, 0303 health sciences, business.industry, Hematology, General Medicine, Middle Aged, medicine.disease, Thalidomide, 3. Good health, Clinical trial, Regimen, Treatment Outcome, Doxorubicin, 030220 oncology & carcinogenesis, Monoclonal, Prednisone, Female, Multiple Myeloma, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e1c1a0103ebd62cfdd0ad071e031465Test
https://doi.org/10.1111/ejh.13683Test

4

Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data

المؤلفون: Roman Hájek, Vladimir Maisnar, I. Agirrezabal, Luděk Pour, Sebastian Gonzalez-McQuire, Jiri Minarik, Ivan Spicka, P. Jandova, Marco Campioni

المصدر: The European Journal of Health Economics

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Palliative care, Cost effectiveness, Cost-Benefit Analysis, Economics, Econometrics and Finance (miscellaneous), Registry of Monoclonal Gammopathies, Dexamethasone, Disease-Free Survival, Drug Costs, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Multiple myeloma, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, 030212 general & internal medicine, Registries, Lenalidomide, Survival analysis, ASPIRE, Czech Republic, Original Paper, business.industry, Health Policy, Carfilzomib, Real world, medicine.disease, I19, Discontinuation, chemistry, 030220 oncology & carcinogenesis, Cost-effectiveness, Quality-Adjusted Life Years, Neoplasm Recurrence, Local, business, Incremental cost-effectiveness ratio, Oligopeptides, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bd614268e91592797a30f671d424a2aTest
http://europepmc.org/articles/PMC7072050Test

5

Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma

المساهمون: Millennium Pharmaceuticals, Takeda Pharmaceutical Company

المصدر: Digital.CSIC. Repositorio Institucional del CSIC
instname

مصطلحات موضوعية: Adult, Boron Compounds, Male, Cancer Research, medicine.medical_specialty, Glycine, Effectiveness, Routine clinical practice, Ixazomib, Dexamethasone, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Multiple myeloma, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Proteasome inhibitor, Prospective Studies, Adverse effect, Lenalidomide, Aged, Aged, 80 and over, business.industry, General Medicine, Middle Aged, medicine.disease, Progression-Free Survival, Clinical trial, Oncology, chemistry, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Monoclonal, Female, Observational study, Relapsed/refractory, Neoplasm Recurrence, Local, business, 030215 immunology, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbb2eb25f28b45fad8a319815d33ed8eTest
http://hdl.handle.net/10261/261619Test

6

Systemic inflammatory response with high CRP values as the dominant symptom of multiple myeloma

المؤلفون: Zdeněk Král, Viera Sandecká, Mojmír Moulis, Zdeněk Adam, Martin Stork, Alena Buliková, Lucie Říhová, Zdeněk Řehák, Renata Koukalová, Miroslav Tomiška, Marta Krejčí, František Folber, Z. Čermáková, Luděk Pour

المصدر: Vnitřní lékařství. 65:37-44

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e260e07c1df32f2807546c48d0ff310Test
https://doi.org/10.36290/vnl.2019.009Test

7

Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data

المؤلفون: Jiri Minarik, R Velichova, Alexandra Jungova, Ivan Spicka, Vladimir Maisnar, Evžen Gregora, Roman Hájek, Martin Stork, Sabina Ševčíková, Lucie Brozova, Tomas Jelinek, Luděk Pour

المصدر: Neoplasma. 67(1)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4f61dd562a85e74df2b5b7635264010Test
https://pubmed.ncbi.nlm.nih.gov/31829027Test

8

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

المصدر: Leukemia
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

مصطلحات موضوعية: Adult, Oncology, Cancer Research, medicine.medical_specialty, Population, Salvage therapy, Dexamethasone, Disease-Free Survival, Bortezomib, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Recurrence, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, education, Multiple myeloma, Aged, Lenalidomide, Aged, 80 and over, Salvage Therapy, education.field_of_study, business.industry, Hematology, Middle Aged, medicine.disease, Carfilzomib, 3. Good health, Surgery, Treatment Outcome, Prior Therapy, chemistry, 030220 oncology & carcinogenesis, Original Article, Multiple Myeloma, business, Oligopeptides, 030215 immunology, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::699f25105680fe0f9a501ec835ea46dfTest
https://doi.org/10.1038/leu.2016.186Test

9

Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients

المؤلفون: Luděk Pour, Zdeněk Král, Viera Sandecká, Lucie Brozova, Zdeněk Adam, Sabina Ševčíková, Martin Stork, Marta Krejčí, R Velichova

المصدر: Neoplasma. 65(4)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bd9b5a919b01350308fa2d545986193Test
https://pubmed.ncbi.nlm.nih.gov/29940759Test

10

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

المصدر: Leukemia
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Phases of clinical research, Gastroenterology, Dexamethasone, Bortezomib, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Biomarkers, Tumor, Humans, Lenalidomide, Chromosome Aberrations, Salvage Therapy, business.industry, Hazard ratio, Remission Induction, Hematology, Pomalidomide, Prognosis, Carfilzomib, 3. Good health, Surgery, Thalidomide, Survival Rate, Oncology, chemistry, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Cytogenetic Analysis, Female, Original Article, Neoplasm Grading, Neoplasm Recurrence, Local, business, Multiple Myeloma, Oligopeptides, 030215 immunology, medicine.drug, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5085835f8dacb4137116949dc42fe6c3Test
https://pubmed.ncbi.nlm.nih.gov/28025582Test

تنقيح النتائج